Imiquimod Patent Expiration
Imiquimod is Used for treating skin conditions caused by certain types of viruses. It was first introduced by Bausch Health Us Llc
Imiquimod Patents
Given below is the list of patents protecting Imiquimod, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zyclara | US10918635 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | Apr 30, 2030 | Bausch |
| Zyclara | US11202752 | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy | Apr 30, 2030 | Bausch |
| Zyclara | US11850245 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | Apr 30, 2030 | Bausch |
| Zyclara | US10238644 | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod | Dec 11, 2029 | Bausch |
| Zyclara | US11318130 | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod | Dec 11, 2029 | Bausch |
| Zyclara | US8222270 | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod | Dec 11, 2029 | Bausch |
| Zyclara | US8236816 | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod | Dec 11, 2029 | Bausch |
| Zyclara | US8299109 | Method of treating actinic keratosis with 3.75% imiquimod cream | Dec 11, 2029 | Bausch |
| Zyclara | US10238645 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | Aug 18, 2029 | Bausch |
| Zyclara | US8598196 | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy | Aug 18, 2029 | Bausch |
| Aldara |
US7696159 (Pediatric) | Treatment for basal cell carcinoma |
Oct 01, 2024
(Expired) | Bausch |
| Aldara | US7696159 | Treatment for basal cell carcinoma |
Apr 01, 2024
(Expired) | Bausch |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Imiquimod's patents.
Latest Legal Activities on Imiquimod's Patents
Given below is the list recent legal activities going on the following patents of Imiquimod.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Mar, 2024 | US8299109(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Jan, 2024 | US8236816(Litigated) |
| Patent Issue Date Used in PTA Calculation Critical | 26 Dec, 2023 | US11850245 |
| Recordation of Patent Grant Mailed Critical | 26 Dec, 2023 | US11850245 |
| Mail Patent eGrant Notification | 26 Dec, 2023 | US11850245 |
| Email Notification Critical | 26 Dec, 2023 | US11850245 |
| Recordation of Patent eGrant | 26 Dec, 2023 | US11850245 |
| Patent eGrant Notification | 26 Dec, 2023 | US11850245 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Dec, 2023 | US8222270 |
| Email Notification Critical | 07 Dec, 2023 | US11850245 |
Imiquimod's Family Patents
Explore Our Curated Drug Screens
Imiquimod Generic API Manufacturers
Several generic applications have been filed for Imiquimod. The first generic version for Imiquimod was by Fougera Pharmaceuticals Inc and was approved on Feb 25, 2010. And the latest generic version is by Taro Pharmaceutical Industries Ltd and was approved on Jan 26, 2021.
Given below is the list of companies who have filed for Imiquimod generic, along with the locations of their manufacturing plants worldwide.
1. APOTEX INC
Apotex Inc has filed for 1 generic for Imiquimod. Given below are the details of the strengths of this generic introduced by Apotex Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5% | cream | Prescription | TOPICAL | AB | Apr 6, 2012 |
Manufacturing Plant Locations New
Apotex Inc's manufacturing plants are situated in 1 country - Canada. Given below are the details of these plant locations as well as the firm names of Apotex Inc as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| Canada |
| |||||||
2. COSETTE
Cosette Pharmaceuticals Inc has filed for 1 generic for Imiquimod. Given below are the details of the strengths of this generic introduced by Cosette.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5% | cream | Discontinued | TOPICAL | N/A | Apr 18, 2011 |
Manufacturing Plant Locations New
Cosette's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Cosette as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
3. ENCUBE
Encube Ethicals Private Ltd has filed for 1 generic for Imiquimod. Given below are the details of the strengths of this generic introduced by Encube.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5% | cream | Discontinued | TOPICAL | N/A | Feb 28, 2011 |
Manufacturing Plant Locations New
Encube's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Encube as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| India |
| |||||
4. FOUGERA PHARMS
Fougera Pharmaceuticals Inc has filed for 1 generic for Imiquimod. Given below are the details of the strengths of this generic introduced by Fougera Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5% | cream | Prescription | TOPICAL | AB | Feb 25, 2010 |
5. GLENMARK PHARMS INC
Glenmark Pharmaceuticals Inc Usa has filed for 1 generic for Imiquimod. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5%
(reference standard) | cream | Prescription | TOPICAL | AB | Mar 6, 2012 |
6. PADAGIS ISRAEL
Padagis Israel Pharmaceuticals Ltd has filed for 1 generic for Imiquimod. Given below are the details of the strengths of this generic introduced by Padagis Israel.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5% | cream | Prescription | TOPICAL | AB | Sep 7, 2010 |
Manufacturing Plant Locations New
Padagis Israel's manufacturing plants are situated in 1 country - Israel. Given below are the details of these plant locations as well as the firm names of Padagis Israel as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| Israel |
| |||
7. STRIDES PHARMA
Strides Pharma Global Pte Ltd has filed for 1 generic for Imiquimod. Given below are the details of the strengths of this generic introduced by Strides Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5% | cream | Discontinued | TOPICAL | N/A | Jun 24, 2014 |
Manufacturing Plant Locations New
Strides Pharma's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Strides Pharma as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
| India |
| |||||
8. TARO
Taro Pharmaceutical Industries Ltd has filed for 2 different strengths of generic version for Imiquimod. Given below are the details of the strengths of this generic introduced by Taro.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5% | cream | Prescription | TOPICAL | AB | Apr 15, 2011 |
| 3.75% | cream | Prescription | TOPICAL | AB | Jan 26, 2021 |
Manufacturing Plant Locations New
Taro's manufacturing plants are situated in 3 countries - United States, Israel, Canada. Given below are the details of these plant locations as well as the firm names of Taro as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
| Israel |
| |||||
| Canada |
| |||||